Stock VPTDF VENTRIPOINT DIAGNOSTICS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Ventripoint Diagnostics Ltd. OTC Markets

Equities

VPTDF

CA92281P2008

Delayed OTC Markets
Other stock markets
 15:19:00 2024-07-16 EDT 		5-day change 1st Jan Change
0.1542 USD -3.62% Intraday chart for Ventripoint Diagnostics Ltd. -1.97% -32.43%
06-13 Ventripoint Diagnostics Ltd. Appoints Matt Dobson as Marketing Director CI
05-31 Ventripoint Diagnostics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Ventripoint Diagnostics Ltd. Appoints Matt Dobson as Marketing Director
Ventripoint Diagnostics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Ventripoint Diagnostics Ltd. Submits Next Generation of Software, VMS+4.0, to the U.S. Food and Drug Administration
Duke University Health Center Purchases Ventripoint's AI Heart-Scan Technology
Ventripoint Diagnostics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Ventripoint Diagnostics Ltd. Releases Significant Upgrade to the Design and Function of Its Whole-Heart Analysis System (VMS+3.2)
Ventripoint Diagnostics Ltd. Showcases A.I. Powered Heart-Scanning Technology at International Cardiology Conferences
Ventripoint Diagnostics Ltd. Appoints Hugh Macnaught as Interim CEO
Ventripoint Diagnostics Ltd. Appoints Hugh Macnaught as President
The Paediatric Heart Centre At the Medical University of Vienna Has Chosen to Adopt the Vms+ as Its Cardiac Diagnostic Tool
VentriPoint Diagnostics Ltd. Announces Appointment of Dr. Luc Mertens to Clinical Advisory Board
VentriPoint Diagnostics Ltd. Enters into A Global Distribution and Marketing Agreement with Ascend Cardiovascular
VentriPoint Diagnostics Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
VentriPoint Diagnostics Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Ventripoint Welcomes Evelina London Children's Hospital as Newest Vms+ User
Ventripoint Diagnostics Ltd. Announces That Ventripoint and Ascend Cardiovascular, Llc Have Developed A New Integrated Product
Ventripoint Diagnostics Ltd. Announces Collaboration with Ascend Cardiovascular
VentriPoint Diagnostics Ltd. Announces Purchase of VMS+ by Medical Center ­University of Freiburg
VentriPoint Diagnostics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
VentriPoint Diagnostics Ltd. Auditor Raises 'Going Concern' Doubt
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VPT Stock
  4. VPTDF Stock
  5. News Ventripoint Diagnostics Ltd.
  6. Other languages